Artiva Biotherapeutics (NASDAQ:ARTV) Director Ra Capital Management, L.P. Buys 15,102 Shares

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Director Ra Capital Management, L.P. bought 15,102 shares of the firm’s stock in a transaction on Friday, July 10th. The shares were purchased at an average cost of $8.97 per share, with a total value of $135,464.94. Following the transaction, the director directly owned 16,811,021 shares in the company, valued at approximately $150,794,858.37. This trade represents a 0.09% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Ra Capital Management, L.P. also recently made the following trade(s):

• On Monday, July 13th, Ra Capital Management, L.P. bought 6,552 shares of Artiva Biotherapeutics stock. The shares were acquired at an average cost of $8.94 per share, with a total value of $58,574.88.
• On Friday, June 26th, Ra Capital Management, L.P. acquired 1,876 shares of Artiva Biotherapeutics stock. The shares were bought at an average cost of $8.98 per share, with a total value of $16,846.48.
• On Thursday, June 25th, Ra Capital Management, L.P. purchased 31,000 shares of Artiva Biotherapeutics stock. The stock was bought at an average cost of $8.88 per share, with a total value of $275,280.00.
• On Tuesday, June 16th, Ra Capital Management, L.P. purchased 124,893 shares of Artiva Biotherapeutics stock. The shares were purchased at an average cost of $8.89 per share, for a total transaction of $1,110,298.77.
• On Monday, June 15th, Ra Capital Management, L.P. bought 15,414 shares of Artiva Biotherapeutics stock. The stock was purchased at an average price of $8.99 per share, for a total transaction of $138,571.86.
• On Friday, June 12th, Ra Capital Management, L.P. bought 391,019 shares of Artiva Biotherapeutics stock. The stock was purchased at an average price of $8.57 per share, for a total transaction of $3,351,032.83.
• On Thursday, June 11th, Ra Capital Management, L.P. purchased 548,580 shares of Artiva Biotherapeutics stock. The stock was acquired at an average cost of $7.91 per share, with a total value of $4,339,267.80.
• On Wednesday, June 10th, Ra Capital Management, L.P. purchased 103 shares of Artiva Biotherapeutics stock. The shares were acquired at an average price of $7.00 per share, with a total value of $721.00.
• On Tuesday, June 9th, Ra Capital Management, L.P. acquired 479,039 shares of Artiva Biotherapeutics stock. The shares were acquired at an average price of $6.91 per share, for a total transaction of $3,310,159.49.
• On Monday, May 11th, Ra Capital Management, L.P. acquired 6,510,416 shares of Artiva Biotherapeutics stock. The stock was acquired at an average cost of $11.52 per share, for a total transaction of $74,999,992.32.

Artiva Biotherapeutics Price Performance

Shares of NASDAQ ARTV opened at $9.35 on Wednesday. The stock has a market capitalization of $231.13 million, a P/E ratio of -2.64 and a beta of 2.18. The company has a 50-day moving average price of $9.01 and a 200-day moving average price of $7.02. Artiva Biotherapeutics, Inc. has a 1 year low of $2.04 and a 1 year high of $14.53.

Artiva Biotherapeutics (NASDAQ:ARTV) last posted its earnings results on Friday, May 8th. The company reported ($0.95) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.88) by ($0.07). As a group, equities research analysts anticipate that Artiva Biotherapeutics, Inc. will post -2.45 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research analysts recently issued reports on ARTV shares. Wall Street Zen cut Artiva Biotherapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, May 17th. Weiss Ratings restated a “sell (d-)” rating on shares of Artiva Biotherapeutics in a research note on Friday, April 24th. Wedbush lifted their price objective on shares of Artiva Biotherapeutics from $23.00 to $40.00 and gave the stock an “outperform” rating in a report on Monday, May 11th. Needham & Company LLC reiterated a “buy” rating and issued a $41.00 target price on shares of Artiva Biotherapeutics in a research note on Monday, June 8th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Artiva Biotherapeutics in a report on Tuesday, May 26th. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Artiva Biotherapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $39.00.

Institutional Trading of Artiva Biotherapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the business. Dimensional Fund Advisors LP bought a new stake in Artiva Biotherapeutics during the first quarter worth $131,000. Sanctuary Advisors LLC bought a new position in Artiva Biotherapeutics in the 1st quarter valued at $139,000. Simplify Asset Management Inc. purchased a new stake in shares of Artiva Biotherapeutics during the 1st quarter valued at $150,000. OMERS ADMINISTRATION Corp purchased a new stake in shares of Artiva Biotherapeutics during the 4th quarter valued at $91,000. Finally, Marshall Wace LLP bought a new stake in shares of Artiva Biotherapeutics during the 4th quarter worth $341,000.

About Artiva Biotherapeutics

Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company’s proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches.

Artiva’s pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors.